Wiki · EIM
33 questions, drawn from this site's literature corpus. Draft pages are not yet clinician-reviewed.
Does intravenous iron sucrose lead to faster hemoglobin recovery than oral ferrous sulfate in patients with iron deficiency anemia secondary to IBD draftWhat is the evidence that early biologic therapy prevents long‑term structural damage progression in axial spondyloarthritis compared with delayed initiation after conventional treatment failure draftDoes azathioprine cause a higher risk of liver enzyme elevation compared to 6‑mercaptopurine in IBD patients draftIn patients with CD who develop mild transaminitis after starting azathioprine, is dose reduction or addition of allopurinol preferred draftWhat is the evidence that pre‑treatment TPMT genotyping reduces the incidence of hepatotoxicity in patients starting azathioprine for IBD draftWhat proportion of EIMs in IBD are considered activity‑dependent versus independent of intestinal inflammation draftDoes IPAA lead to higher rates of EIM remission than permanent ileostomy in patients undergoing colectomy for CD draftIn patients with CD and active ankylosing spondylitis scheduled for subtotal colectomy, should spontaneous postoperative resolution of the spondylitis be expected or biologic therapy continued draftIn patients with CD who have active perianal fistulas and uveitis, which biologic, anti‑TNF, ustekinumab, or vedolizumab, is preferred to address both intestinal and ocular inflammation draftWhat is the evidence that anti‑TNF agents are more effective than JAK inhibitors in patients with IBD and concomitant PSC draftHow does the prevalence of PSC in UC compare between North American and European cohorts draftIn patients with CD who develop new-onset arthritis, should it be attributed to shared immune pathways and treated with methotrexate or should separate rheumatologic evaluation be considered draftWhat are the typical clinical features that distinguish erythema nodosum from other panniculitis conditions draftIs infliximab more effective than adalimumab at inducing clinical remission of metastatic cutaneous Crohn's lesions draftIn metastatic cutaneous Crohn's disease with active colonic inflammation, should systemic immunosuppression be prioritized for skin lesions or for bowel disease draftDoes adalimumab cause a higher rate of paradoxical psoriasis compared to infliximab in patients with CD draftWhat is the evidence that switching from infliximab to certolizumab reduces the risk of paradoxical psoriasis compared to continuing infliximab draftIn patients with UC and new-onset asymmetric oligoarthritis, is an anti‑TNF agent or sulfasalazine preferred first draftIn patients with CD whose peripheral arthritis persists despite adequate biologic therapy, is adding low-dose systemic corticosteroids more effective than switching to another biologic draftIn patients with moderate‑to‑severe pyoderma gangrenosum, how does oral prednisone compare to oral cyclosporine in achieving clinical remission at 12 weeks draftIn an elderly patient with pyoderma gangrenosum and significant renal impairment, is topical tacrolimus ointment a safer alternative to systemic immunosuppressants for ulcer control draftWhat is the evidence that infliximab offers superior remission rates compared with adalimumab in refractory pyoderma gangrenosum draftIn adults with granulomatous anterior uveitis and positive HLA-B27, should topical steroids alone be initiated or systemic immunosuppression added immediately draftWhat is the recommended duration of pharmacologic thromboprophylaxis after major colorectal surgery draftIn patients undergoing elective colectomy for UC with a history of prior DVT, should extended‑duration pharmacologic prophylaxis be prescribed beyond the standard postoperative period draftIn patients with CD on biologic therapy with acute abdominal pain and suspected obstruction, should empiric anticoagulation for possible mesenteric venous thrombosis be initiated before imaging confirms diagnosis draftWhat are the most common EIMs of IBD draftWhy is PSC considered an EIM of IBD, and how does it behave draftIn adults with IBD taking chronic corticosteroids and azathioprine, does vaccination with the recombinant zoster vaccine (Shingrix) reduce the incidence or severity of herpes zoster compared to no vaccination draftWhat is the incidence of VTE in paediatric-onset IBD draftIn patients with IBD and PSC, does prophylactic ursodeoxycholic acid (UDCA) reduce the risk of progression to cholangiocarcinoma compared to no UDCA draftIn pediatric patients with PSC, does the presence or absence of IBD affect long-term prognosis regarding liver transplantation draftWhich malignancy shows a higher standardized incidence ratio in patients with UC and PSC: biliary cancer or CRC draft